» Articles » PMID: 35754121

Understanding Immunological Origins of Atopic Dermatitis Through Multi-omic Analysis

Overview
Specialty Pediatrics
Date 2022 Jun 27
PMID 35754121
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The pathophysiology of atopic dermatitis (AD) is multifactorial, impacted by individual medical, demographic, environmental, and immunologic factors. This study used multi-omic analyses to assess how host and microbial factors could contribute to infant AD development.

Methods: This longitudinal cohort study included 129 term infants, identified as AD (n = 37) or non-AD (n = 92) using the Infant Feeding Practices-II survey and review of medical records. Standardized surveys were used to assess medical and demographic traits (gestational age, sex, race, maternal AD, and atopy family history), and environmental exposures (delivery method, maternal tobacco use, pets, breastfeeding duration, and timing of solid food introduction). Saliva was collected at 6 months for multi-omic assessment of cytokines, microRNAs, mRNAs, and the microbiome. The contribution of each factor to AD status was assessed with logistic regression.

Results: Medical, demographic, and environmental factors did not differ between AD and non-AD infants. Five "omic" factors (IL-8/IL-6, miR-375-3p, miR-21-5p, bacterial diversity, and Proteobacteria) differed between groups (p < .05). The severity of AD was positively associated with levels of miR-375-3p (R = .17, p = .049) and Proteobacteria (R = .22, p = .011), and negatively associated with levels of miR-21-5p (R = .20, p = .022). Multi-omic features accounted for 17% of variance between groups, significantly improving an AD risk model employing medical, demographic, and environmental factors (X  = 32.47, p = .006).

Conclusion: Interactions between the microbiome and host signaling may predispose certain infants to AD by promoting a pro-inflammatory environment.

Citing Articles

Resolution of Chronic Inflammation, Restoration of Epigenetic Disturbances and Correction of Dysbiosis as an Adjunctive Approach to the Treatment of Atopic Dermatitis.

Livshits G, Kalinkovich A Cells. 2024; 13(22).

PMID: 39594647 PMC: 11593003. DOI: 10.3390/cells13221899.


Vinpocetine, a phosphodiesterase 1 inhibitor, mitigates atopic dermatitis-like skin inflammation.

Lee Y, Song J, Lee S, Lee Y, Hwang K, Lee J Korean J Physiol Pharmacol. 2024; 28(4):303-312.

PMID: 38926838 PMC: 11211756. DOI: 10.4196/kjpp.2024.28.4.303.


Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis.

Rusinol L, Puig L Int J Mol Sci. 2024; 25(2).

PMID: 38256115 PMC: 10815999. DOI: 10.3390/ijms25021042.


Diseases from the Spectrum of Dermatitis and Eczema: Can "Omics" Sciences Help with Better Systematics and More Accurate Differential Diagnosis?.

Spiewak R Int J Mol Sci. 2023; 24(13).

PMID: 37445645 PMC: 10342122. DOI: 10.3390/ijms241310468.


Intrinsic Effects of Exposome in Atopic Dermatitis: Genomics, Epigenomics and Regulatory Layers.

Grafanaki K, Antonatos C, Maniatis A, Petropoulou A, Vryzaki E, Vasilopoulos Y J Clin Med. 2023; 12(12).

PMID: 37373692 PMC: 10299550. DOI: 10.3390/jcm12124000.